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Abstract
Background: The pathobiology of schizophrenia is still unclear. Its current treatment mainly depends on antipsychotic 
drugs. A leading adverse effect of these medications is the acquired long QT syndrome, which results from the 
blockade of cardiac HERG1 channels (human ether-a-go-go-related gene potassium channels 1) by antipsychotic 
agents. The HERG1 channel is encoded by HERG1 (KCNH2, Kv11.1) gene and is most highly expressed in heart and brain. 
Genetic variations in HERG1 predispose to acquired long QT syndrome. We hypothesized that the blockade of HERG1 
channels by antipsychotics might also be significant for their therapeutic mode of action, indicating a novel 
mechanism in the pathogenesis of schizophrenia.
Methods: We genotyped four single nucleotide polymorphisms (SNPs) in 7q36.1 region (two SNPs, rs1805123 and 
rs3800779, located on HERG1, and two SNPs, rs885684 and rs956642, at the 3'-downstream intergenic region) and then 
performed single SNP and haplotype association analyses in 84 patients with schizophrenia and 74 healthy controls 
after the exclusion of individuals having prolonged or shortened QT interval on electrocardiogram.
Results: Our analyses revealed that both genotype and allele frequencies of rs3800779 (c.307+585G>T) were 
significantly different between populations (P = 0.023 and P = 0.018, respectively). We also identified that two 
previously undescribed four-marker haplotypes which are nearly allelic opposite of each other and located in 
chr7:150225599-150302147bp position encompassing HERG1 were either overrepresented (A-A-A-T, the at-risk 
haplotype, P = 0.0007) or underrepresented (C-A-C-G, the protective haplotype, P = 0.005) in patients compared to 
controls.
Conclusions: Our results indicate that the potassium channel gene HERG1 is related to schizophrenia. Our findings 
may also implicate the whole family of HERG channels (HERG1, HERG2 and HERG3) in the pathogenesis of psychosis 
and its treatment.
Background
Schizophrenia (SCH) is a serious mental disorder affect-
ing around 0.5% of the general population worldwide [1].
Despite being a clinically recognized entity for more than
a century, the etiopathogenesis of SCH still remains a
mistery [1,2]. SCH seems to be a multifactorial disorder,
in which the contribution of both genetic and environ-
mental factors and their interplay are important [1,3]. Lit-
tle is known about the underlying environmental factors,
and the rare genetic variants so far disclosed as suscepti-
bility factors are neither necessary nor sufficient for the
disease [1]. As yet, there is no identified biological marker
with which a biologically valid diagnosis can be made
[1,2]. The current treatment depends on antipsychotic
drugs which have antidopaminergic properties (D2
receptor blockade) as the main feature, with or without a
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certain degree of additional antiserotonergic effects (5-
HT2A receptor blockade) in particular [4,5]. The high
remission but low recovery rate by antipsychotic therapy
[6,7] is probably due to their insufficient specificity for
the complex mechanism underlying SCH, which might
go beyond the most frequently-described hyperdopamin-
ergic pathophysiology [2,8]. The unspecificity in dop-
aminergic-blocking effects of antipsychotic drugs also
seems to be the cause of their main side-effects, the
extrapyramidal syndromes (EPS) [9,10]. A further leading
drug-induced adverse effect is the acquired long QT
(LQT) syndrome, which results from the blockade of a
type of voltage-gated potassium channel in the heart,
namely the cardiac HERG1 (human ether-a-go-go-related
gene potassium channel 1) channel, by antipsychotic
agents [11-13].
HERG1 (also referred as KCNH2 or Kv11.1) belongs to
a particular subtype known as H or Kv11 subfamily of the
voltage-gated potassium channels [14], along with
HERG2 (KCNH6, Kv11.2) and HERG3 (KCNH7, Kv11.3)
[15]. According to the mostly stated view in literature, the
HERG channels characteristically exhibit a tetrameric
composition of one main alpha-subunit (HERG1, HERG2
or HERG3 protein), which comprises six transmem-
brane-spanning domains denoted S1-S6, and one auxil-
iary beta-subunit (minK, MiRP1 or MiRP2 protein)
(Figure 1) [11,16-18]. The co-assembly of HERG channels
through different alpha-subunits of the same subfamily,
alternative isoforms of a given alpha-subunit or diverse
auxiliary beta-subunits gives rise to their enormous
structural and functional variability among various tis-
sues and cells as well as among individuals [19-21]. These
channels play an important role in the repolarization of
the cellular membrane potential of excitable cells, such as
cardiac, neuronal and smooth muscle cells [16]. Hence,
HERG1 is expressed at the highest levels in heart and
brain, whereas HERG2 and HERG3 are expressed exclu-
sively in brain [22-25]. Notably, HERG1 channel is
responsible for the rapid delayed rectifier current (IKr),
which is a major component of the repolarization of car-
diac action potentials [16,18]. The HERG1 protein, alpha-
subunit of the HERG1 channel, is encoded by HERG1
gene, which contains 15 exons on 7q36.1 region and gives
rise to at least three distinct isoforms by alternative splic-
ing (the canonical form, 4282 bp) [26,27]. To date, more
than 300 genetic variations in HERG1 have been found
either to cause the congenital form or to predispose to
the acquired form of the so-called LQT and short QT
(SQT) syndromes [28-30]. These syndromes are charac-
terized by cardiac arrhythmias and a prolonged or short-
hened QT interval on electrocardiogram (ECG), which
reflects the duration of cardiac repolarization [29,30].
Whilst the congenital form of the syndromes comprises
inherited phenotypes caused by HERG1 variations, the
acquired form encompasses reversible phenotypes
induced most often through the blockade of HERG1
channels, with or without an underlying predisposition
resulting from HERG1  variations, by certain drugs, in
particular the antipsychotics [12,30,31].
An old and enduring notion in psychiatry is that the
therapeutic and adverse effects of antipsychotic drugs
frequently co-occur [32,33], indicating that they work
through more or less similar or overlapping mechanisms.
This is true in the case of their antidopaminergic proper-
ties which produce therapeutic effects on one hand, but
cause EPS side effects on the other [10,34]. By analogy, we
hypothesized that the blockade of HERG1 channels by
antipsychotics, which is responsible for the acquired LQT
side effects, might also be involved in the therapeutic
mechanism of these drugs, thereby providing a clue to the
core pathogenesis of SCH. We therefore studied a num-
ber of genetic variations in and around the HERG1 gene
by single SNP and haplotype association analyses in a
population of patients with SCH. Recently, Huffaker et al.
[35] studied two family-based cohorts of European ances-
try and three case-control cohorts also of European
ancestry (Germans, Armenians and Italians). They iden-
tified six single nucleotide polymorphisms (SNPs) to be
associated with SCH in family-based studies, four SNPs
in the German case-control study and four SNPs in the
meta-analysis including all five clinical data sets, and
reported  HERG1 as a previously undescribed potential
susceptibility gene for SCH [35].
Methods
Patients and controls
The study population consisted of 87 unrelated Turkish
male inpatients with SCH (mean age = 34,91 ± 6,98 years)
recruited from the Bakirkoy Research and Training Hos-
pital for Psychiatry, Neurology and Neurosurgery
(BRSHH) in Istanbul, a specialized referral center of the
Turkish Ministry of Health. The inclusion criteria were to
be aged between 18 and 65 years, to have an informed
written consent by themselves and/or by their legal
supervisors and to have a diagnosis of SCH. The diagno-
sis of SCH was made in accordance with the Diagnostic
and Statistical Manual of Mental Disorders - Fourth Edi-
tion (DSM-IV) in consensus by two psychiatrists who
interviewed the patients independently using the Struc-
tured Clinical Interview for DSM-IV (SCID-I) [36] Cases
were screened to exclude substance-induced psychotic
disorder, psychosis due to a general medical condition,
and co-morbid psychiatric disorder. The control popula-
tion included 77 Turkish males (mean age = 34,23 ± 8,20
years) collected from the Control Subjects Biobank at the
Research Institute for Experimental Medicine of Istanbul
University. None of the controls in that biobank has a
known or identified psychiatric disorder, neurologicalAtalar et al. Behavioral and Brain Functions 2010, 6:27
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disease or medical condition. Patients and controls were
recruited from Istanbul metropolitan area. Both study
populations do well represent the general population of
Turkey as Istanbul receives substantial internal migration
from almost all regions of Turkey since 1950s.
Exclusion of subjects with a long or short QT interval on 
electrocardiogram (ECG)
As many genetic variations in the HERG1 gene are related
with congenital or acquired forms of LQT and SQT syn-
dromes, we excluded the patients and controls that had a
prolonged or shortened QT interval on their ECG
recordings (the main diagnostic criterium for LQT or
SQT syndromes, respectively [29]) in order to discard any
incidental confounding effect which could arise from a
putative HERG1-LQT/SQT association rather than a real
HERG1-SCH relationship. A standard 12-lead resting
ECG was obtained from each patient and control with an
automated electrocardiograph (ECG-9620 Cardifax,
Nihan Kohden, Japan) at a paper speed of 25 mm/s. The
QT interval and the so-derived QTc value (corrected QT
according to heart rate by the Bazett's formula [29,37],
QTc = QT/√RR) were measured automatically by the
Modular ECG Analysis System (MEANS). In the interna-
tional guidelines [38,39] or related literature [13,29], the
widely accepted threshold values are QTc > 450 ms in
men for prolonged QT interval and QTc < 300 ms for
shortened QT interval. ECG recordings of the patients
and controls were evaluated accordingly, and three
patients and three controls having QTc > 450 ms or < 300
ms were excluded. The remaining 84 patients (mean age
= 34,37 ± 6,70 years) and 74 controls (mean age = 34,32 ±
8,11 years) formed the ultimate study groups.
Selection of single nucleotide polymorphisms (SNPs) for 
association analyses
A large-scale, two-step design, population-based Euro-
pean study (KORA), conducted by Pfeufer et al. [40], was
previously performed in order to determine the associa-
tions between genetic variations in four potassium chan-
nel genes, including HERG1, and QT interval
prolongation. In the present work, we investigated four
out of five SNPs, located in and around HERG1, that were
found to be significantly associated with QT interval pro-
longation in the screening phase of the mentioned study.
In order to minimize false-negative error rate, we chose
the SNPs from the "screening" rather than the subsequent
"confirmation" phase. We excluded the fifth SNP found to
be significant in the study of Pfeufer et al. [40] as it was
located within another gene (NOS3), 5'-upstream of
Figure 1 Tetrameric organization and membrane topology of HERG1 channel. a: Orthogonal view from the extracellular side demonstrating the 
tetrameric organization of HERG1 channel. b: Longitudinal view through the channel, taken from the longitudinal section shown at the top, displaying 
the membrane topology of only two reciprocal components across the pore of the tetrameric HERG1 channel. The channel exhibits a tetrameric com-
position of one main alpha-subunit (HERG1 protein, shown as α and in plain gray) and one auxiliary beta-subunit (minK or MiRP1 protein, shown as β 
and in dotted gray). The alpha-subunit is composed of six transmembrane-spanning domains (labelled S1-S6), S1-S4 being the voltage-sensing do-
main and S5-S6 the pore-forming domain. The beta-subunit comprises one transmembrane-spanning domain. The NH2 and COOH termini are also 
shown. α, alpha-subunit; β, beta-subunit; P, pore.
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HERG1. Among the four SNPs intended to be analyzed in
our study, two were located on HERG1 gene (rs1805123
in the exon 11, and rs3800779 in the intron 2), and the
other two SNPs (rs885684 and rs956642) were located at
the 3'-downstream intergenic region of HERG1 (see Fig-
ure 2). The SNPs span ~76 kb on genomic DNA in
chr7:150225599-150302147 bp position.
DNA extraction and SNP genotyping
Genomic DNA was extracted from 10 ml fresh peripheral
blood using the QIAamp DNA Blood Mini Kit (Qiagen,
Germany) according to the manifacturer's protocol.
Twenty microliters of genomic DNA from each patient
and control subject were prepared at a concentration of 2
ng/L in v-bottomed 96-well microtitre plates. Repeat and
blank samples were also included in the plates as experi-
mental controls. The microtitre plates were then trans-
ported to the KBiosciences Company, Cambridge, UK,
via a private courier and in accordance with the national
and international legal regulations and technical require-
ments for international transfer of biological materials.
All of the genotyping was performed by the KBiosciences
using the KASP technology, which is a competitive allele-
specific PCR incorporating a FRET quencher cassette,
according to the protocol used by the company [41].
Statistics for single SNP and haplotype association analyses
Deviations from Hardy-Weinberg Equilibrium (HWE)
were assessed for quality control of genotyping proce-
dures among patients and controls separately. SNPs were
excluded from the analysis if they were out of HWE (P <
0.05) or had a minor allele frequency of less than 5%. The
allele and genotype frequencies were obtained by direct
counting. We used SPSS 11.5 software for statistical anal-
yses. The P values were corrected by means of Bonferroni
correction for multiple testing. We used Haploview soft-
ware [42] to reconstruct haplotypes and estimate haplo-
type frequencies in the unrelated patients and controls. In
order to obtain a measure of significance corrected for
multiple testing, we ran 10000 permuations to compute P
values using the Haploview program. Comparisons of the
distributions of the allele, genotype and haplotype fre-
quencies were performed using the chi-square test. Sta-
tistical significance was defined as P < 0.05.
Ethical issues
This study was approved by the Ethics Committee of
BRSHH, and was in compliance with the World Medical
Association (WMA) Declaration of Helsinki. Written
informed consent was obtained from all subjects and/or
their legal supervisors.
Figure 2 Location of the four SNPs analyzed in and around the HERG1 gene on 7q36.1 region. a: The 100 kb genomic region (shown as hori-
zontal gray line) including the HERG1 gene (shown as gray rectangle) on 7q36.1. b: The organization of exons (shown as gray boxes) and introns 
(shown as horizontal gray lines) of the HERG1 gene. The four SNPs analyzed span ~76 kb on genomic DNA in chr7:150225599-150302147 bp position. 
Two SNPs (rs885684 and rs956642) are located at the 3'-downstream intergenic region of HERG1, and the other two SNPs (rs1805123 and rs3800779) 
are located respectively in exon 11 and intron 2 of the gene. Black circles () represent the SNP locations, and the rs numbers of SNPs are shown along 
the relevant arrows. SNP, single nucleotide polymorphism.
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Results
Single SNP association analysis
The χ2 goodness-of-fit test showed that the four SNPs
genotyped were within the distribution expected accord-
ing to HWE in both the patient (rs885684: χ2 = 3.728, P =
0.053; rs956642: χ2 = 0.705, P = 0.401; rs1805123: χ2 =
1.185, P = 0.276; rs3800779: χ2 = 0.247, P = 0.619) and the
control (rs885684: χ2 = 3.151, P = 0.075; rs956642: χ2 =
0.786,  P  = 0.375; rs1805123: χ2  = 0.035, P  = 0.852;
rs3800779: χ2 = 3.736, P = 0.053) populations. The geno-
type and allele frequencies of the individual SNPs and the
results of the association analyses between patients and
controls are summarized in Table 1. The minor allele fre-
quencies were more than 5%. Neither the genotype nor
the allele frequencies of rs885684, rs956642 and
rs1805123 differ between patients and controls. However,
both the genotype and allele frequencies of rs3800779
(c.307+585G>T) were significantly different between the
populations (see Table 1). The GG genotype was found to
be less frequent and GT and TT genotypes more fre-
quent, whereas the frequency of the G allele was lower
and the frequency of the T allele was higher in patients
than in controls (P = 0.023 and P = 0.018, respectively).
Haplotype association analysis
Pair-wise linkage disequilibrium (LD) was calculated
between all pairs of SNPs using the Haploview program
and the results are shown in Figure 3. All four SNPs were
part of one haplotype block and fairly tight LD was
observed in most SNP pairs (see Figure 3). Analyses of
sliding windows of two- and three-SNP haplotypes did
not reveal any significant difference in haplotype distri-
butions between patients and controls (data not shown).
Four-SNP haplotypes with frequencies ≥1% are listed in
Table 2. The analysis of the four-SNP haplotypes dis-
played significant differences in the distributions of two
Table 1: Genotype and allele frequencies and results of the association analysis between patients and controls.
SNP Genotype frequencies, n (%) χ2 P-value Allele frequencies χ2 P-value
Genotype SCH (n = 84) CTR (n = 74) Allele SCH (n = 84) CTR (n = 74)
rs885684 AA 37 (44.0) 34 (45.9) 1.06 0.302 A/C 0.696/0.304 0.642/0.358 1.06 0.303
AC 43 (51.2) 27 (36.5)
CC 4 (4.8) 13 (17.6)
rs956642 AA 37 (44.0) 28 (37.8) 2.38 0.123 A/G 0.679/0.321 0.595/0.405 2.41 0.120
AG 40 (47.6) 32 (43.2)
GG 7 (8.3) 14 (19.0)
rs1805123 AA 51 (60.7) 39 (52.7) 2.12 0.145 A/C 0.792/0.208 0.723/0.277 2.03 0.153
AC 31 (36.9) 29 (39.2)
CC 2 (2.4) 6 (8.1)
rs3800779 GG 37 (44.1) 49 (66.2) 5.15 0.023 G/T 0.673/0.327 0.791/0.209 5.52 0.018
GT 39 (46.4) 19 (25.7)
TT 8 (9.5) 6 (8.1)
SNP, single nucleotide polymorphism; SCH, patients with schizophrenia; CTR, control subjects.
Alleles shown are major/minor.
The P-values given are corrected by means of Bonferroni correction.
Association reaching nominal significance (P < 0.05) is shown in bold.Atalar et al. Behavioral and Brain Functions 2010, 6:27
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haplotypes, A-A-A-T and C-A-C-G, between the popula-
tions (see Table 2). The A-A-A-T haplotype was overrep-
resented, whereas the C-A-C-G haplotype was
underrepresented in patients as compared to controls (P
= 0.0007, P = 0.005, respectively), suggesting the former
to be a high-risk and the latter a low-risk haplotype. It is
of note that the potentially "protective" haplotype C-A-C-
G is an allelic opposite at all loci but the second locus of
the potentially "at-risk" haplotype A-A-A-T. The C-G-C-
G haplotype that is the exact allelic opposite of the A-A-
A-T haplotype was absent in our patient and control pop-
ulations.
Discussion
In this study, we reasoned that a particular mechanism
(HERG1 channel blockade, for example) responsible for a
prevailing adverse effect of antipsychotic drugs (acquired
LQT in this case) is also likely to be one unique mecha-
nism by which their therapeutic effects are mediated, and
that, by inference, this might contribute to our under-
s t a n d i n g  o f  t h e  u n d e r l y i n g  m e c h a n i s m s  i n  S C H .  T h i s
assumption led us to investigate the putative association
of HERG1 gene with SCH. To discard any incidental con-
founding association of HERG1 with LQT or SQT syn-
dromes among study and control populations, we
excluded those patients and controls with LQT or SQT
intervals on ECG. We chose the SNPs to be analyzed (two
located on HERG1 and two at the 3'-downstream region
of the gene) on the basis of their association with QT
interval prolongation according to a large-scale, two-step
design, population-based European study [40]. Our anal-
yses revealed that two haplotypes, which were nearly
allelic opposite of each other and composed of the four
SNPs investigated, were either overrepresented (A-A-A-
T, the at-risk haplotype) or underrepresented (C-A-C-G,
the protective haplotype) in patients with SCH as com-
pared to control subjects. Because the relevant haplotype
block which spans a ~76 kb region of genomic DNA in
chr7:150225599-150302147 bp position does not include
any other genes, this finding might be essentially attrib-
uted to either HERG1  or its surrounding regulatory
sequences. In support of this, we report that one of the
two SNPs located on HERG1 (rs3800779 in the intron 2,
c.307+585G>T) shows significant differences in both
genotype and allele distributions between patients and
controls. Our results thereby identify the HERG1 gene as
a susceptibility factor for SCH and implicate the contri-
bution of HERG1 channels to its pathobiology.
Despite intensive research, the pathobiology of SCH
still remains obscure [1,2]. The bulk of current evidence
gathered from a wide range of studies suggests that SCH
is a disorder of neurodevelopment involving the dysfunc-
tion of multiple neurotransmitters in neural circuits par-
ticularly concerning the dopaminergic, serotonergic,
glutamatergic and GABAergic systems within or between
cortical-prefrontal and subcortical-limbic regions
[2,7,43,44]. The biological characteristics of HERG chan-
nels are broadly in concordance with the above-men-
tioned features of SCH pathobiology. ERG1  (this is
homologous to the human gene HERG1, referring its
orthologs in all species) is expressed at high levels
throughout the brain besides the heart, specifically, in the
hippocampus, neocortex, hypothalamus, thalamus,
amygdala, substantia nigra, red nucleus and cerebellum
[22,23,25,45,46]. The other two members of the ERG
genes family, ERG3 and ERG2 (homologous terms in all
species for HERG3 and HERG2, respectively), also have a
m o r e  o r  l e s s  w i d e s p r e a d  e x p r e s s i o n  i n  t h e  b r a i n
[22,23,45,46] and moreover they seem to be nervous sys-
tem-specific [24]. There is convincing evidence that the
products of these three genes form heterotetramers in
various combinations at specific brain regions where they
Figure 3 Linkage disequilibrium pattern of the SNPs along the 
7q36.1 region encompassing the HERG1 gene. The graphic illus-
trates the one distinct haplotype block defined using the Haploview 
program. The linkage disequilibrium (D') between any two SNPs is 
shown in the cross cell. The darker the color indicates the higher link-
age disequilibrium between any two SNPs. The linkage disequilibrium 
(r2) between any two SNPs is as follows: rs885684-rs956642: 0.191; 
rs885684-rs1805123: 0.277; rs885684-rs3800779: 0.122; rs956642-
rs1805123: 0.081; rs956642-rs3800779: 0.072; rs1805123-rs3800779: 
0.074. SNP, single nucleotide polymorphism.Atalar et al. Behavioral and Brain Functions 2010, 6:27
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co-expressed [45-48], giving rise to multiple heterotetra-
meric ERG channels with functional properties distinct
from those of homotetramers [21,47-49]. All types of
ERG channels studied so far, and particularly the most
studied ERG1 channels, were shown to modify neuronal
excitability and spike frequency adaption [49-53]. ERG1
gene was consistently shown to be expressed in dopamin-
ergic [54] and serotonergic [47] neurons from rat brain
and in GABAergic interneurons from mouse [45] and rat
brains [22,46]. It is of particular note that both an experi-
mental study [54] and a computational model [55]
showed the modulation of dopamine neurons by ERG
channels. The neuronal expression of all three ERG
genes, in particular including the most studied ERG1, was
found to be developmentally regulated [23,56].
Recently, Huffaker et al. [35] reported HERG1 as a pre-
viously undescribed potential susceptibility gene for
SCH. The authors genotyped, in a family-based associa-
tion study, the haplotype-tagging SNPs in 10 previously
reported candidate genes and their results revealed the
7q36.1 region to be strongly associated with SCH. They
then performed initial studies of 43 or 40 SNPs in the
7q36.1 region of two family-based cohorts of European
ancestry. Subsequently, seven SNPs in HERG1, selected
according to initial results, were analyzed in three case-
control cohorts, also of European ancestry (Germans,
Armenians and Italians). They identified six SNPs to be
associated with SCH in family-based studies, four SNPs
in the German case-control study and four SNPs in the
meta-analysis including all five clinical data sets, although
none of the SNPs were significant in the Armenian and
Italian samples. Interestingly, across all their samples, the
HERG1  S N P  m o s t  s t r o n g l y  a s s o c i a t e d  w i t h  S C H  w a s
rs3800779, which is also the SNP showing unique signifi-
cance towards the same direction of association in our
study. Nevertheless, their three-marker haplotype analy-
sis did not show an association that was more significant
than individual SNPs. The authors also investigated
HERG1 expression in brain and found expression of full-
length isoform 1A (KCNH2-1A or HERG1-1A) to be sig-
nificantly lower in patients with SCH than in controls,
but they were unable to detect an association with the
Table 2: Four-SNP haplotype frequencies and results of the association analysis between patients and controls.
Haplotype Frequency Case, control ratios χ2 P-value
A-A-A-G 0.206 0.217, 0.194 0.26 0.610
C-A-C-G 1 0.177 0.121, 0.241 7.79 0.005
A-G-A-G 0.177 0.146, 0.212 2.36 0.124
A-G-A-T 0.139 0.114, 0.167 1.81 0.178
C-A-A-G 0.126 0.138, 0.112 0.49 0.484
A-A-A-T 1 0.094 0.147, 0.035 11.46 0.0007
A-A-C-T 0.020 0.033, 0.005 3.12 0.077
A-G-C-G 0.019 0.017, 0.022 0.10 0.752
A-A-C-G 0.017 0.024, 0.008 1.25 0.263
C-G-A-T 0.012 0.022, 0.002 2.52 0.112
SNP, single nucleotide polymorphism.
Case refers to patients with schizophrenia, and control refers to control subjects.
Haplotypes listed are only those with a frequency ≥1%.
The P-values given are based on 10000 permutations using the Haploview program.
Associations reaching nominal significance (P < 0.05) are shown in bold.
1Note that C-A-C-G haplotype is an allelic opposite at all, but the second, loci of A-A-A-T haplotype. C-G-C-G haplotype that is the exact allelic 
opposite of A-A-A-T haplotype was absent in our patient and control populations.Atalar et al. Behavioral and Brain Functions 2010, 6:27
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HERG1 risk genotypes that they identified. Following fur-
ther investigation aimed at determining the apparently
complicated gene processing, they ultimately discovered
a previously undescribed brain-specific isoform
(KCNH2-3.1 or HERG1-3.1) which lacks the first two
exons and introns of the full-length gene but contains the
downstream region. Furthermore, they determined that
expression of HERG1-3.1 was increased in brain of
patients compared to controls and that this was signifi-
cantly associated with HERG1  risk genotypes. Taken
together, the authors argued that overexpression of this
newly identified isoform is related to the pathogenesis of
SCH, and that the mechanism by which the disease-asso-
ciated SNPs contribute to increased risk involves the reg-
ulation of HERG1-3.1 transcription by a splicing
mechanism yet to be determined.
Although our starting point was different from that of
Huffaker et al. [35] (hypothesis-driven in our case and
evidence-based in theirs), we identified the same gene,
HERG1, in association with SCH. The 7q36.1 regions
investigated by us (~76 kb) and by Huffaker et al. [35]
(~65 kb) are presented in Figure 4a. The two regions
overlap well on HERG1, however that investigated by
Huffaker et al. [35] extends in the 5'-upstream direction,
whilst ours extends towards the region 3'-downstream of
the gene. As an independent research group we confirm
Huffaker et al. [35] regarding the association of SCH with
HERG1  and specifically the HERG1  SNP rs3800779
which shows higher significance in their study and
unique significance in ours towards the same direction of
association. We also present the association of HERG1
with SCH in Turkish population, as was shown by Huf-
faker et al. [35] in American and German populations,
but not in Armenians and Italians. In addition to single
SNP association, we furthermore report two previously
undescribed SCH-associated four-marker haplotypes on
7q36.1 region encompassing HERG1, that were more sig-
nificant than unique significant SNP (the at-risk haplo-
type A-A-A-T and the protective haplotype C-A-C-G).
Our study differed from Huffaker et al. [35] by excluding
patients and controls having LQT or SQT interval on
ECG recordings, in order to discard any incidental con-
founding association of HERG1 with underlying LQT or
SQT syndromes which could have remained occult
within the study and control groups. This provided to us
more specific and statistically significant findings, in par-
ticular the identification of two unique SCH-associated
haplotypes (A-A-A-T/C-A-C-G), nearly allelic opposite
of each other. This specific finding further widens the
implications introduced by Huffaker et al. [35] regarding
the possibilities of a more extended involvement of genes
in 7q36.1 other than HERG1 and of a more complicated
regulation of HERG1  expression other than splicing
mechanism in SCH. As concerns our first inference, the
A-A-A-T/C-A-C-G haplotypes extending across a num-
ber of haplotype blocks defined in the CEU population
(Utah residents in USA with Northern and Western
European ancestry from the Centre d'Etude du Polymor-
phisme Humaine collection) of the International HapMap
Project [42] (Figure 4b) towards the intergenic region 3'-
downstream of HERG1 may be a part of even larger SCH-
associated haplotypes that might be related with more
than one gene (Figure 4a) and/or with the copy number
variation (CNV) of ~125 kb of length (Variation 3711) in
7q36.1. With regard to our second inference, the A-A-A-
T/C-A-C-G haplotypes may also signify the contribution
of CNV 3711, which is partly inserted into HERG1 (~21.5
kb from its 3'-end, Figure 4a), to the pathogenesis of SCH
by affecting gene expression, which is a well-known
mechanism of CNVs [57,58]. Taken together, further to
the comments of Huffaker et al. [35] on their results, our
findings make it plausible a more extended involvement
of 7q36.1 region apart from HERG1 and a more compli-
cated regulation of HERG1 transcription other than splic-
ing mechanism in SCH.
Our study also justifies the usefulness of our prelimi-
nary rationale envisaging that both an adverse and a ther-
apeutic effect of antipsychotic drugs might depend on a
common mechanism, which could enhance our knowl-
edge about the pathobiology of SCH. Although for many
years it was believed that the prevalent EPS side effects
and the therapeutic effects of antipsychotic drugs could
not be dissociated since the former effects were assumed
to be required for the latter effects [33,59], the recent
introduction of more specific second generation antipsy-
chotic drugs implied otherwise [33,60]. Thereby, our
findings suggest that whilst the blockade of cardiac
HERG1 channels by antipsychotic agents causes acquired
LQT side effects, the blockade of neuronal HERG1 chan-
nels by these drugs might contribute to their therapeutic
effects, as previously proposed by a number of authors
[35,61-63]. Consistently, our findings might have consid-
erable impact on antipsychotic treatment in clinical prac-
tice. Firstly, HERG1  gene variations might predict the
efficacy of an antipsychotic drug in a given patient, in
addition to determining the predisposition of an individ-
ual to acquired LQT syndrome. Secondly, the introduc-
tion of more specific antipsychotic drugs that
preferentially block neuronal rather than cardiac HERG1
channels might reduce the occurrence of acquired LQT
side effects in patients without worsening therapeutic
benefits. Thirdly, specific neuronal HERG1 channel mod-
ifiers could also be developed for the treatment of SCH in
conjunction with antipsychotic drugs in order to improve
the therapeutic outcome. Finally, we propose that a spe-
cific neuronal HERG modifier, especially for HERG3 or
HERG2 channels, might be a more effective and saferAtalar et al. Behavioral and Brain Functions 2010, 6:27
http://www.behavioralandbrainfunctions.com/content/6/1/27
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pharmacological intervention than others [64] in primary
prevention of SCH at high-risk individuals.
Limitations
One limitation of our study is its moderate sample size.
Although the number of our study subjects is generally
regarded as small for association studies, we were able to
confirm the findings reported in larger populations by
Huffaker et al. [35] regarding the association of SCH with
HERG1 and specifically the HERG1 SNP rs3800779. Nev-
ertheless, our study needs to be reproduced in a larger
sample size regarding the identification of two previously
undescribed haplotypes located on 7q36.1 region encom-
passing  HERG1  and more significantly associated with
SCH than individual SNP.
A further limitation of our study is the lack of details on
the ethnic characteristics of our samples. Indeed, consid-
erable mixtures between ethnicities for many generations
prevent to have precise data on the exact ethnic origins of
many people in T urkey. Nevertheless, both patients and
controls were recruited from Istanbul metropolitan area,
and we believe that both populations do well represent
the general population of Turkey and that a possibility of
stratification between populations does not exist in our
samples.
Conclusions
In summary, we have found that a SNP (rs3800779,
c.307+585G>T) located on HERG1 shows significant dif-
ferences in both genotype and allele distributions
Figure 4 Organization of genomic region and localization of haplotype blocks situated between positions 150150-150355 kb in 7q36.1. a: 
A 205 kb part situated between positions 150150-150355 kb of the 7q36.1 genomic region (gray horizontal line at the top), along with the genes ABP1, 
HERG1 (KCNH2), NOS3 and ATG9B located here (gray boxes), is shown. Relative position on 7q36.1 (marked by dotted lines) of the region investigated 
in the present study (~76 kb of length in chr7:150225599-150302147 bp position) is represented by the upper horizontal black line and that of Huffaker 
et al. (~65 kb of length in chr7:150280464-150345679 bp position; see text for the reference) by the lower horizontal black line. Black circles () on the 
upper horizontal black line indicate the locations of four SNPs analyzed in the present study, and the rs numbers of SNPs are presented along the 
relevant arrows. Small vertical lines (?) on the lower horizontal black line indicate the locations of seven SNPs analyzed in all cohorts studied by Huffaker 
et al. rs3800779 is the single common SNP investigated in both studies and showed the higher significance among six significant SNPs found in the 
study of Huffaker et al. and the unique significance among four SNPs analyzed in the present study. Black horizontal rectangle at the bottom shows 
the position on 7q36.1 (marked by dotted lines) of the copy number variation (CNV, Variation 3711) of ~125 kb of length located in this part of the 
genome between positions 150169754-150294630 bp and partly inserted into HERG1 (~21.5 kb from its 3'-end). Three out of four SNPs (except 
rs3800779) that composes the schizophrenia-associated haplotypes A-A-A-T/C-A-C-G identified in the present study are located within this CNV. b: 
Haplotype blocks defined between positions 150150-150355 kb in 7q36.1 genomic region in the CEU population of the International HapMap Project 
http://hapmap.ncbi.nlm.nih.gov are shown. As marked by dotted lines, the schizophrenia-associated A-A-A-T/C-A-C-G haplotypes identified in the 
present study extend across a number of defined haplotype blocks. ABP1, amiloride binding protein 1 gene; NOS3, nitric oxide synthase 3 (endothelial 
cell) gene; ATG9B, nitric oxide synthase 3 antisense gene; SNP, single nucleotide polymorphism; CNV, copy number variation.
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between patients with SCH and control subjects, and we
have also identified two previously undescribed four-
marker haplotypes located on 7q36.1 region in
chr7:150225599-150302147 bp position encompassing
HERG1 and more significantly associated with SCH than
individual SNP (the at-risk haplotype A-A-A-T and the
protective haplotype C-A-C-G, which are nearly allelic
opposite of each other). Our results indicate that the
potassium channel gene HERG1 is associated with SCH,
although this needs to be reproduced in a larger sample
size and in other ethnic groups. Nevertheless, we believe
our findings merit further investigation in order to deter-
mine whether the HERG1 gene is also a common suscep-
tibility factor to psychosis including affective disorders
besides SCH, considering that genetic associations are
generally not specific to one of the traditional diagnostic
categories of functional psychoses [65]. Finally, as the
other two members of the ERG channels family, ERG3
and ERG2, which are known for their widespread expres-
sion in brain, are seemingly nervous system-specific [24]
and form heterotetramers with ERG1 channels [45-48],
we believe that HERG3 and HERG2 genes also need to be
extensively studied in psychotic disorders. Future
research, most importantly a combinatoric approach [66]
integrating the genetics (genetic variation, genetic regula-
tion and epigenetic modification) and the biology (syn-
thesis, trafficking, gating and conductance) of HERG
channels with clinical data, will illuminate their exact lieu
in the pathobiology and treatment of SCH and psychosis.
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